Adenosine A2A receptor antagonists are broad facilitators of antinicotinic neuromuscular blockade monitored either with 2 Hz train-of-four or 50 Hz tetanic stimuli

Clinical and Experimental Pharmacology and Physiology

Volumn 39, Issue 10, 2012, Pages 869-877

  Pereira, Monalisa W ^a   Correia de Sá, Paulo ^b   Alves Do Prado, Wilson ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cisatracurium; d tubocurarine; Fade; Hexamethonium; Pancuronium; Train of four; Train of four fade

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; CISATRACURIUM; HEXAMETHONIUM; METHOCTRAMINE; MUSCARINIC M2 RECEPTOR; PANCURONIUM; PIRENZEPINE; TUBOCURARINE CHLORIDE;

ANIMAL EXPERIMENT; ANTINICOTINIC NEUROMUSCULAR BLOCKING; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HEMIDIAPHRAGM; MALE; MUSCLE CONTRACTION; MUSCLE TONE; NERVE CONDUCTION; NERVE STIMULATION; NEUROMODULATION; NEUROMUSCULAR BLOCKING; NONHUMAN; PHRENIC NERVE; PRESYNAPTIC INHIBITION; RAT;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; DIAPHRAGM; DRUG SYNERGISM; ELECTRIC STIMULATION; HEXAMETHONIUM; MALE; MUSCLE CONTRACTION; NEUROMUSCULAR BLOCKING AGENTS; NEUROMUSCULAR JUNCTION; NICOTINIC ANTAGONISTS; PANCURONIUM; PHRENIC NERVE; RATS; RATS, WISTAR; RECEPTOR, ADENOSINE A2A; RECEPTOR, MUSCARINIC M1; RECEPTOR, MUSCARINIC M2; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; TUBOCURARINE;

EID: 84866791949     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2012.12004.x     Document Type: Article

References (30)

1. Colquhoun D, Mathie A, Mulrine NK, Ogden DC. Studies on single acetylcholine-receptor channels in muscle endplate and sympathetic neurons. In: Sellin LC, Libelius R, Thesleff S (eds). Neuromuscular Junction. Elsevier, Amsterdam. 1989; 217-34.
2. Wessler I, Halank M, Rasbach J, Kilbinger H. Presynaptic nicotine receptors mediating a positive feed-back on transmitter release from the rat phrenic nerve. Naunyn Schmiedebergs Arch. Pharmacol. 1986; 334: 365-72.
3. Faria M, Oliveira L, Timóteo MA, Lobo MG, Correia-de-Sá P. Blockade of neuronal facilitatory nicotinic receptors containing α3β2 subunits contribute to tetanic fade in the rat isolated diaphragm. Synapse 2003; 49: 77-88.
4. Wessler I. Control of transmitter release from the motor nerve by presynaptic nicotinic and muscarinic autoreceptors. Trends Pharmacol. Sci. 1989; 10: 110-4.
5. 3H]-acetylcholine release from the rat motor nerve terminals. Eur. J. Neurosci. 2002; 15: 1728-36.
6. 2A facilitatory adenosine receptor activation balance depends on motor nerve stimulation paradigm at the rat hemidiaphragm. J. Neurophysiol. 1996; 76: 3910-19.
7. 1 receptors at the rat motor endplate. Neurosci. Lett. 2009; 459: 127-31.
8. Kato M, Hashimoto Y, Horinouchi T, Ando T, Ito J, Yamanaka H. Inhibition of human plasma cholinesterase and erythrocyte acetylcholinesterase by nondepolarizing neuromuscular blocking agents. J. Anesth. 2000; 14: 30-4.
9. Bornia ECS, Bando E, Machinski MJ, Pereira MW, Alves-Do-Prado W. Presynaptic M1, M2, and A1 receptors play roles in tetanic fade induced by pancuronium or cisatracurium. J. Anesth. 2009; 23: 513-19.
10. v1 (L-type) influx in myasthenia gravis. J. Neurochem. 2011; 117: 797-811.
11. Alves-Do-Prado W, Corrado AP, Prado WA. Reversal by atropine of tetanic fade induced in cats by antinicotinic and anticholinesterasic agents. Anesth. Analg. 1987; 66: 492-6.
12. Alves-Do-Prado W, Corrado AP, Prado WA. Train-of-four as an index of neuromuscular block in cats: Changes induced by atropine. Braz. J. Med. Biol. Res. 1989; 22: 749-55.
13. Ali HH, Utting JE, Gray C. Stimulus frequency in the detection of neuromuscular block in humans. Br. J. Anaesth. 1970; 42: 967-78.
14. Murphy GS. Residual neuromuscular blockade: Incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol. 2006; 72: 97-109.
15. 2A receptors mediate fade induced by neuromuscular relaxants that exhibit anticholinesterase activity. Clin. Exp. Pharmacol. Physiol. 2011; 38: 164-9.
16. Pereira MW, Bornia E, Correia-de-Sá P, Alves-Do-Prado W. Presynaptic muscarinic and adenosine receptors involved in 2 Hz-induced train-of-four fade caused by antinicotinic neuromuscular relaxants in the rat. Clin. Exp. Pharmacol. Physiol. 2011; 38: 764-70.
17. Padmaja D, Mantha S. Monitoring of neuromuscular junction. Indian J. Anaesth. 2002; 46: 279-88.
18. Bülbring E. Observations on the isolated phrenic nerve diaphragm preparation of the rat. Br. J. Pharmacol. 1946; 1: 38-61.
19. Silva HMV, Ambiel CR, Alves-Do-Prado W. The neuromuscular transmission fade (Wedensky inhibition) induced by l-arginine in neuromuscular preparations from rats. Gen. Pharmacol. 1999; 32: 705-12.
20. Schuh FT. On the inhibition of cholinesterases by pancuronium. Anaesthesist 1977; 26: 125-9.
21. 1 receptors on rat motoneurons. Neurosignals 2005; 14: 262-72.
22. 2A receptor facilitation of acetylcholine release at rat motor nerve endings. J. Physiol. 2003; 549: 399-408.
23. Timóteo MA, Faria M, Correia-de-Sá P. Endogenous adenosine prevents post-tetanic release facilitation mediated by α3α2 nicotinic autoreceptors. Eur. J. Pharmacol. 2003; 464: 115-25.
24. 2a receptor activation modulates nicotinic autoreceptor function at the rat neuromuscular junction. Eur. J. Pharmacol. 1994; 271: 349-55.
25. Cunha RA, Correia-de-Sá P, Sebastião AM, Ribeiro JA. Preferential activation of excitatory adenosine receptors at rat hippocampal and neuromuscular synapses by adenosine formed from released adenine nucleotides. Br. J. Pharmacol. 1996; 119: 253-60.
26. Taylor P Agents acting at the neuromuscular junction and autonomic ganglia. In: Brunton LL, Lazo JS, Parker KL (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn. McGraw-Hill, New York. 2006; 217-36.
27. Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth. Analg. 1980; 59: 935-43.
28. 2A receptors. Neurogastroenterol. Motil. 2009; 21: 1118-e95.
29. 2A receptors: A new strategy for basal ganglia disorders. Recent Pat. CNS Drug Discov. 2007; 2: 1-21.
30. 2A receptor antagonist istradefylline (KW-6002) reduces 'off' time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005). Ann. Neurol. 2008; 63: 295-302.